44th Annual J.P. Morgan Healthcare Conference

Here’s what Aixial do to tackle the feasibility challenges in rare disease clinical trials. Rare disease trials require access-focused strategies

Effective aggregate safety reporting is a cornerstone of patient safety, regulatory compliance, and informed decision-making.

Check out our poster to dive deeper into the study, understand the methodology, and see the results firsthand.

This article outlines Aixial’s comprehensive best practices for operational oversight of safety system lifecycle management.

At Aixial, we conducted up to 150 neurological studies, up to 300 oncology trials in various geographical areas such as Europe, North America, Asia Pacific, thus giving us the opportunity to oversee what works and what doesn’t work in this field.

With deep therapeutic expertise, cross-regional capabilities, and proven operational performance, Aixial is the CRO partner of choice for biotech and pharma sponsors launching complex early phase programs.